Research Analysts Issue Forecasts for Arvinas Q1 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Wedbush boosted their Q1 2025 earnings per share estimates for Arvinas in a research note issued on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.76) per share for the quarter, up from their prior forecast of ($0.93). Wedbush currently has a “Neutral” rating and a $12.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

Other research analysts have also recently issued reports about the company. Morgan Stanley reduced their price target on Arvinas from $48.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. BTIG Research initiated coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target for the company. Stifel Nicolaus reduced their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company set a $26.00 price target on Arvinas and gave the company an “overweight” rating in a research report on Wednesday. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.47.

Arvinas Stock Down 1.4 %

Arvinas stock opened at $8.43 on Monday. Arvinas has a 52 week low of $7.91 and a 52 week high of $45.77. The company has a market capitalization of $579.75 million, a price-to-earnings ratio of -3.04 and a beta of 1.95. The stock has a 50-day moving average price of $17.32 and a 200 day moving average price of $21.84.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the prior year, the business earned ($2.53) earnings per share.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Arvinas during the fourth quarter worth $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after buying an additional 3,047 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in Arvinas during the fourth quarter worth $749,000. Woodline Partners LP boosted its stake in Arvinas by 39.2% during the fourth quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock worth $13,280,000 after buying an additional 194,996 shares during the last quarter. Finally, Twinbeech Capital LP acquired a new position in Arvinas during the fourth quarter worth $3,146,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Insider Transactions at Arvinas

In other news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now directly owns 159,121 shares of the company’s stock, valued at $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,572 shares of company stock valued at $695,030 over the last ninety days. Insiders own 5.23% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.